(formerly AcelleRX Therapeutics)



Cleveland, OH

Juventas Therapeutics is developing novel biopharmaceutical therapies for regenerative medicine using technology exclusively licensed from the Cleveland Clinic. The Company’s lead product, Stromal Derived Factor-1 (SDF-1), has been shown to significantly increase cardiac function through promoting cell survival and revascularization after myocardial infarction.